The text has been copied to the clipboard
Back
Full-text
Journal article

Summary statement on screening for prostate cancer in Europe.

  • Heijnsdijk EAM Department of Public Health, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.
  • Bangma CH Department of Urology, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.
  • Borràs JM Department of Health, Catalan Institute of Oncology, Avinguda de la Granvia de l'Hospitalet 199-203, Barcelona, 08908, Spain.
  • de Carvalho TM Department of Public Health, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.
  • Castells X Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, Barcelona, 08003, Spain.
  • Eklund M Department of medical epidemiology and biostatistics, Karolinska Institutet, Karolinska vägen, Solna, Stockholm, 171 76, Sweden.
  • Espinàs JA Department of Health, Catalan Institute of Oncology, Avinguda de la Granvia de l'Hospitalet 199-203, Barcelona, 08908, Spain.
  • Graefen M Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52 Building O43, Hamburg, 20246, Germany.
  • Grönberg H Department of medical epidemiology and biostatistics, Karolinska Institutet, Karolinska vägen, Solna, Stockholm, 171 76, Sweden.
  • Lansdorp-Vogelaar I Department of Public Health, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.
  • Leeuwen PJV Department of Urology, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.
  • Nelen V Provinciaal Instituut voor Hygiëne, Kronenburgstraat 45, Antwerp, 2000, Belgium.
  • Recker F Department of Urology, Kantonsspital Aarau, Tellstrasse 25, Aarau, 5001, Switzerland.
  • Roobol MJ Department of Urology, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.
  • Vandenbulcke P Agentschap Zorg en gezondheid, Lange Kievitstraat 111-113, Antwerp, 2018, Belgium.
  • de Koning HJ Department of Public Health, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.
Show more…
  • 2017-10-13
Published in:
  • International journal of cancer. - 2018
PSA
mass-screening
mortality
prostate cancer
Aged
Early Detection of Cancer
Europe
Humans
Kallikreins
Male
Middle Aged
Prostate-Specific Antigen
Prostatic Neoplasms
Randomized Controlled Trials as Topic
English The European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that Prostate-Specific Antigen (PSA) based screening results in a significant prostate cancer mortality reduction. Although there are concerns on overdiagnosis and overtreatment, it has been shown that the benefits can outweigh the harms if screening is stopped in older ages to prevent overdiagnosis. A limited screening program (for example screening at ages 55-59 years), including active surveillance for men with low-risk tumors, can even be cost-saving, compared with testing in an opportunistic setting in the wrong ages, as currently in Europe. Further improvements are expected in the use of active surveillance and in discrimination between indolent and significant disease due to new biomarkers and magnetic resonance imaging. However, these future developments are no reason to postpone feasibility studies of high-quality PSA screening and reduce opportunistic testing at old ages.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/93353
Export to…
JSON data
Dublin Core
BibTeX
RIS (Zotero, …)
Statistics
Document views: 77 File downloads:
  • Full-text: 0